Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT00044018 | CDC-501 Therapy in Relapsed or Refractory Multiple Myeloma | PHASE2 | COMPLETED | 102 | — | — | Apr 1, 2002 | Feb 15, 2007 | Nov 12, 2019 | 4 | United States |
M-Protein response evaluated every 4 weeks through urine and serum electrophoresis.
| Name | Type | Description |
|---|---|---|
| CDC-501 | DRUG | - |
* Subject must be diagnosed with multiple myeloma (with measurable M-Protein in serum and/or urine), and be considered to have disease progression after at least two cycles of treatment or have relapsed after treatment. * Subject must understand and voluntarily sign an informed consent document. * S...